Spotlight On... Odoreader showing promise as urological 'smell' test for prostate cancer; Sensus files for up to $23M IPO; EndoChoice launches endoscopy software; and more...

A urological "smell" test for prostate cancer is snaking its way through the R&D process. The University of the West of England's Urological Institute team at Southmead Hospital and the Bristol Royal Infirmary said a pilot of the diagnostic showed promise on 155 men, 58 of whom had prostate cancer and 24 of whom had bladder cancer. "There is an urgent need to identify these cancers at an earlier stage when they are more treatable as the earlier a person is diagnosed the better. After further sample testing the next step is to take this technology and put it into a user friendly format. With help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient's bedside, in a doctor's surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results," said study collaborator and University of Liverpool professor Chris Probert. Professor Norman Ratcliffe of the University of the West of England described the Odoreader as an electronic nose to sense cancer, saying, "The Odoreader has a 30 metre column that enables the compounds in the urine to travel through at different rates thus breaking the sample into a readable format. This is then translated into an algorithm enabling detection of cancer by reading the patterns presented. The positioning of the prostate gland which is very close to the bladder gives the urine profile a different algorithm if the man has cancer." More

@FierceMedDev: ICYMI yesterday: Israeli upstart raises $15M for U.S. pivotal trial of bioresorbable cartilage implant. Article | Follow @FierceMedDev

@EmilyWFierce: In this week's Dx Digest, $ILMN strikes a new sequencing deal and the Obama admin. calls for more Zika testing. More | Follow @EmilyWFierce

> Sensus Healthcare has filed for an IPO to raise up to $23 million to back its low-energy X-ray systems to treat common skin conditions. SEC filing

> EndoChoice ($GI) has launched its Lumos imaging software as part of its Fuse Full Spectrum Endoscopy platform; it's designed to analyze and enhance the vascularity, surface texture, and color of abnormal tissue. More

> Berkeley, CA-based suitX has won the $1 million top prize in the international Robotics for Good Competition for its lightweight, pediatric medical exoskeleton, suitX. More

Biotech News

@FierceBiotech: ICYMI: Just how well do you think biopharma is handling the gender diversity issue? - interesting comments coming in. Article | Follow @FierceBiotech

@JohnCFierce: Two more IPOs out. It's like the Great Escape: AveXis and Proteostasis survive the market storm, raise $145M for R&D. Story | Follow @JohnCFierce

@DamianFierce: No better illustration of the monstrousness of capitalism than the fact that we're all at work on a Kanye album release day. | Follow @DamianFierce

> JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials. Report

> With an eye on growing the pipeline, Szela axes staffers in Aegerion reorg. Article

> FierceBiotech Radio on pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars. Listen/Subscribe

Pharma News

@FiercePharma: Phibro disappoints as quarterly results reflect shift away from antibiotics. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: FDA warning letter says data falsification rampant at IPCA. Some senior managers involved. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Novartis bolsters its home-turf advantage in psoriasis with Cosentyx DTC push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Big Pharma shells out big campaign dollars to presidential candidates. Report

> Mylan snags Meda, advances its OTC ambitions, with $7.2B deal. Article

CRO News

> Catalent posts flat revenue as currency woes bite into growth. Article

> Genomics England picks Icon as its first CRO partner. Report

> Quintiles bets on a big 2016 as revenue rolls in. More

> Recipharm commits $45M to counteract fake drugs. Story

> CRO Pharmaron acquires U.K.-based Quotient Bioresearch. Article

Pharma Manufacturing News

> Recipharm puts up $45M to enhance track-and-trace capabilities. Report

> Regulator suspends Spanish drugmaker over 'critical quality defects.' News

> Qualicaps gets Latin American foothold with acquisition of Brazil's Genix. More

> Regulator suspends Spanish drugmaker over 'critical quality defects.' Story

> Catalent France plant that was victim of sabotage getting back online. Article

Pharma Asia News

> FDA maintains tight grip on Indian and Chinese products. Report

> China drug safety improving, CFDA says. Item

> Sanofi banks on Philippines to lead public Dengvaxia rollout. More

> Japan's Sumitomo Dainippon ready for U.S. acquisitions. Story

> Chugai Alecensa PhIII trial halted early as patients show significant improvement. Article